Taletrectinib is a targeted therapeutic agent that exerts its effects primarily by inhibiting the overactivation of the MET protein. It is indicated for patients with non-small cell lung cancer (NSCLC) associated with specific gene mutations, such as MET exon 14 skipping mutation. This medication must be used as directed by a physician, and the dosage must not be adjusted without medical authorization.
Functions and Mechanism of Action
Targeted Inhibition
It selectively inhibits the MET receptor tyrosine kinase, blocks downstream signaling pathways, and suppresses the proliferation and metastasis of tumor cells.
Precision Therapy
It is administered to tumor patients with MET gene abnormalities in a targeted manner, reducing damage to normal cells.
Indications
Non-Small Cell Lung Cancer
It is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer positive for MET exon 14 skipping mutation.
Some studies support its potential efficacy in patients with MET amplification or overexpression.
Other Solid Tumors
The efficacy of taletrectinib in the treatment of MET-driven tumors such as gastric cancer and renal cell carcinoma is currently being explored in clinical trials.
Precautions for Use
Strict Medical Supervision
The indication must be confirmed based on genetic testing results, and an individualized treatment regimen shall be formulated by a physician.
Adverse Reaction Management
Common adverse reactions include edema, nausea, fatigue, etc., most of which are controllable.
For severe adverse reactions (such as liver injury and interstitial lung disease), the medication must be discontinued immediately and medical attention sought promptly.
Drug-Drug Interactions
Concomitant use with strong CYP3A inhibitors or inducers should be avoided, as it may affect the therapeutic efficacy or increase the risk of toxicity.
Patient Guidance
During medication
Regular monitoring of liver function, electrolytes and electrocardiogram (ECG) is required to assess the therapeutic response.
Medical consultation reminder
Contact a physician immediately in case of dyspnea, persistent edema or unexplained fever.
Lifestyle recommendations
Maintaining a low-salt diet and moderate physical activity helps alleviate drug-related edema.
Taletrectinib is a prescription drug and must be used under the guidance of an oncologist. Complete genetic testing and a comprehensive medical evaluation are required prior to the initiation of treatment.
